TCGA-AR-A5QP-01A-11R-A28M-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 40
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.220
- P53_PATHWAY+0.160
- BILE_ACID_METABOLISM+0.150
- PANCREAS_BETA_CELLS+0.130
- APICAL_SURFACE+0.120
- TNFA_SIGNALING_VIA_NFKB+0.100
- APICAL_JUNCTION+0.090
- COAGULATION+0.080
- DNA_REPAIR+0.080
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.080
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.530
- INTERFERON_GAMMA_RESPONSE-0.460
- G2M_CHECKPOINT-0.450
- MTORC1_SIGNALING-0.400
- MITOTIC_SPINDLE-0.370
- E2F_TARGETS-0.360
- HEDGEHOG_SIGNALING-0.320
- PROTEIN_SECRETION-0.290
- UNFOLDED_PROTEIN_RESPONSE-0.280
- ANDROGEN_RESPONSE-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-GM-A3XG-01A-31R-A24H-07 | — | A | 0.890 |
| 2 | TCGA-OL-A66K-01A-11R-A29R-07 | — | B | 0.868 |
| 3 | TCGA-W8-A86G-01A-21R-A36F-07 | — | A | 0.839 |
| 4 | TCGA-EW-A424-01A-11R-A24H-07 | — | B | 0.834 |
| 5 | TCGA-E2-A14U-01A-11R-A22K-07 | — | A | 0.833 |
| 6 | TCGA-GM-A3NY-01A-11R-A21T-07 | — | B | 0.822 |
| 7 | TCGA-E2-A570-01A-11R-A29R-07 | — | B | 0.818 |
| 8 | TCGA-D8-A73X-01A-11R-A32P-07 | — | B | 0.813 |
| 9 | TCGA-AC-A3TN-01A-11R-A22K-07 | — | B | 0.813 |
| 10 | TCGA-GM-A5PX-01A-12R-A28M-07 | — | A | 0.812 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| COAGULATION | 0.080 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.060 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.040 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.030 | Inavolisib | — uncovered |